Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Sphingosine kinase" patented technology

Sphingosine kinase (SphK) is a conserved lipid kinase that catalyzes formation sphingosine-1-phosphate (S1P) from the precursor sphingolipid sphingosine. Sphingolipid metabolites, such as ceramide, sphingosine and sphingosine-1-phosphate, are lipid second messengers involved in diverse cellular processes. There are two forms of SphK, SphK1 and SphK2. SphK1 is found in the cytosol of eukaryotic cells, and migrates to the plasma membrane upon activation. SphK2 is localized to the nucleus.

Indole compound as well as preparation method and application thereof

The invention provides an indole compound as well as a preparation method and application thereof. The structural formula of the compound is shown as a formula (I), a formula (II) or a formula (III). The compound provided by the invention is used as an ATP (adenosine triphosphate) competitive sphingosine kinase 1 (SphK1) or 2 (SphK2) inhibitor, and shows strong enzyme inhibition activity and an effect of resisting tumor cell proliferation. Experiments prove that the indole compound provided by the invention has the potential to be developed into an anti-tumor therapeutic drug and an anti-pulmonary arterial hypertension therapeutic drug, and a new direction is provided for the field of anti-cancer therapeutic drugs. The preparation method of the compound is simple, low in cost, free of dangerous reagents and suitable for industrial production.
Owner:HEBEI UNIVERSITY

Sphingosine kinase 2 inhibitor for treating coronavirus infection

ActiveUS12551469B2Medical devicesAntiviralsSphingosine Kinase 2Pharmacy medicine
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Owner:REDHILL BIOPHARMA LTD

Lotus leaf extract, preparation method thereof and application of lotus leaf extract as active ingredient of sphingosine kinase 1 agonist

The invention provides a lotus leaf extract, a preparation method thereof and application of the lotus leaf extract as an active ingredient of a sphingosine kinase 1 agonist, the lotus leaf extract is obtained by mixing, fermenting and culturing lotus leaf powder and bacterial strain fermentation liquor of bacillus subtilis, and the lotus leaf extract is enriched with nuciferine with higher content. The nano vesicles which are uniformly distributed and have the average diameter of 90 to 180nm are reserved; the lotus leaf extract can be used as an SPHK1 agonist, and an autophagy-lysosome pathway is activated by activating an SPHK1 pathway, so that abnormal accumulation of cell lipid is effectively inhibited, and a new thought is provided for research and development of skin oil control products.
Owner:EAST CHINA UNIV OF SCI & TECH +1

4-substituted phenylacetamides, processes for their preparation and use thereof

The application provides a 4-substituted phenylacetamide compound and a preparation method and application thereof, and a structural formula of the compound is shown as formula (I) or (II). The compound provided by the application is a kind of sphingosine kinase 2 (SphK2) targeted small molecule, can effectively inhibit SphK2 enzyme activity and human hepatoma (HepG2), murine hepatoma (Hepa1-6), human colon cancer (HCT116), murine colon cancer (MC-38), cervical cancer (MCF-7), gastric cancer (HGC-27) and other cancer cell proliferation and migration, and the inhibiting effect is better than that of a known inhibitor ABC294640, has the potential to be developed into a new anticancer drug. The synthesis steps of the compound are simple, the requirement for equipment is low, and the operation is simple, so that the yield of the reaction can be greatly improved, and the production cost is further saved.
Owner:HEBEI UNIVERSITY

Compositions and methods for the prevention and treatment of obesity and obesity-induced disease

The present disclosure relates to compositions and methods useful for the treatment and / or prevention of obesity and obesity-related diseases in a subject in need thereof. In various embodiments, the present disclosure relates to uses of compounds that are inhibitors of sphingosine kinase-2 (SphK2), dihydroceramide desaturase (DES1) and / or hexosylceramide synthase (GCS), such as opaganib, in the treatment and / or prevention of obesity and obesity- related diseases.
Owner:APOGEE BIOTECHNOLOGY CORP